Disease Behavior and Treatment Response of Special Histological Types of Triple-Negative Breast Cancer
出版年份 2022 全文链接
标题
Disease Behavior and Treatment Response of Special Histological Types of Triple-Negative Breast Cancer
作者
关键词
-
出版物
Clinical Breast Cancer
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-08-20
DOI
10.1016/j.clbc.2022.08.006
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Rare Breast Cancer Subtypes
- (2021) Sarah Jenkins et al. Current Oncology Reports
- Triple‐negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple‐negative breast cancers
- (2020) Cletus A. Arciero et al. JOURNAL OF SURGICAL ONCOLOGY
- Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas
- (2020) Xiangjie Sun et al. MODERN PATHOLOGY
- Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1
- (2020) Emarene Kalaw et al. BRITISH JOURNAL OF CANCER
- Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components
- (2020) Huang-Chun Lien et al. VIRCHOWS ARCHIV
- The genomic landscape of metastatic histologic special types of invasive breast cancer
- (2020) Fresia Pareja et al. npj Breast Cancer
- Metaplastic breast carcinoma: a clinical-pathologic study of 97 cases with subset analysis of response to neoadjuvant chemotherapy
- (2019) Min Han et al. MODERN PATHOLOGY
- Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes
- (2019) Hervé Bonnefoi et al. BRITISH JOURNAL OF CANCER
- Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy
- (2019) Zahraa Al-Hilli et al. BREAST CANCER RESEARCH AND TREATMENT
- Prognosis in triple‐negative apocrine carcinomas of the breast: A population‐based study
- (2019) Wenyu Wu et al. Cancer Medicine
- Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification
- (2018) Isabel Echavarria et al. CLINICAL CANCER RESEARCH
- Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis
- (2018) Matthew N. Mills et al. EUROPEAN JOURNAL OF CANCER
- Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
- (2018) Tiffany A. Traina et al. JOURNAL OF CLINICAL ONCOLOGY
- Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes
- (2018) Nancy Tray et al. BREAST
- Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer
- (2017) Reva K. Basho et al. JAMA Oncology
- A Clinicopathologic Analysis of 45 Patients With Metaplastic Breast Carcinoma
- (2016) Ashley Cimino-Mathews et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor–Positive Subset of Triple-Negative Breast Cancers
- (2016) Anne M. Mills et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
- (2016) H. Bonnefoi et al. ANNALS OF ONCOLOGY
- Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm
- (2016) Lynn Jongen et al. BREAST CANCER RESEARCH AND TREATMENT
- Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1
- (2016) Upasana Joneja et al. JOURNAL OF CLINICAL PATHOLOGY
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
- (2016) Brian D. Lehmann et al. PLoS One
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
- (2013) A. Gucalp et al. CLINICAL CANCER RESEARCH
- Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity
- (2012) J. Moroney et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now